Biologic therapies are revolutionising severe asthma management, showcasing potential for remission, but cost and equitable ...

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells, enhancing ...

Interleukin-1 receptor-associated kinase 4 is critical in the modulation of inflammatory responses through Toll-like receptor and IL-1R signaling.

The molecular mechanisms of HSP47 induction in intestinal fibrosis related to CD, however, remain unclear. Here we investigated the role of interleukin (IL)-17A-induced HSP47 expression in intestinal ...

The global Tacrolimus Market was valued at USD 6600.11 million in 2023 and is likely to reach USD 10823.72 million by 2032, increasing at a CAGR of 5.65% from 2024 to 2032.United States, Phoenix, Nov.

The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...

The FDA has accepted for review the resubmitted sBLA for dupilumab for the treatment of chronic spontaneous urticaria.

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) ...

Type 2 diabetes (T2D) and obesity (OB) are associated with chronic low-grade inflammation and increased fracture risk. In vitro studies showed that inflammation induces bone erosion and inhibits bone ...

Principal Financial Group Inc. reduced its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...